AOD-9604
Also known as: Anti-Obesity Drug 9604, hGH fragment 176-191 analog
AOD-9604 is a modified fragment of human growth hormone that was once trialled for obesity. It is not approved as a medicine in Australia.
- Category
- Metabolic / Fat Loss
- Reported half-life
- Not well established
- Common forms
- Research-grade lyophilised powder (not approved), Research-grade vials (not approved)
- Research status
- A modified hGH fragment once trialled for obesity that did not gain approval as an obesity medicine. Not approved as a medicine in Australia; treated as a research compound.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in early research to be investigated for fat-loss effects
- Reported to influence fat metabolism without growth-hormone-like effects on blood sugar
- Reported in some studies to be explored for cartilage or joint research
How it is reported to work
AOD-9604 is described as a synthetic analogue of the C-terminal fragment of human growth hormone (residues 176-191). It is proposed to stimulate fat breakdown and limit fat formation while reportedly lacking the broader growth-promoting effects of full growth hormone. These mechanisms are reported from research and are not established in an approved therapy.
Background
AOD-9604 is a modified fragment of human growth hormone that was investigated for obesity in earlier clinical research. It did not progress to approval as an obesity medicine and is not approved as a medicine in Australia. This page is educational and is not medical advice; it does not recommend use.
What the research shows
AOD-9604 was reported in early research to be of interest for fat metabolism, and some studies explored other applications. These are reported research findings, not established outcomes, and the compound was not approved for obesity. Evidence in humans is limited.
| Feature | Reported in research |
|---|---|
| Origin | hGH C-terminal fragment analogue |
| Original focus | Obesity |
| Approval | Not approved as a medicine |
What people use it for (reported)
In online discussion, AOD-9604 is reported to be of interest for fat-loss goals because of its origin as a growth-hormone fragment. As an unapproved research compound it has no approved indication in Australia. Material described online as “AOD-9604” is not a verified, approved product, so its identity, purity and contents cannot be assumed, which is why independent testing is discussed in this community.
Things to be aware of
Because AOD-9604 is unapproved, its long-term safety in humans is not established, and the limited reported effects may not reflect what is sold informally. Reported effects on this page are not confirmed facts; they summarise what research and discussion describe. Anyone with weight or metabolic concerns should consult a qualified healthcare professional for individualised guidance. This article is educational, does not recommend any dose, and does not tell anyone to obtain or use it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported interest in fat breakdown without growth-hormone-like effects on blood sugar
- Reported in early research to be explored for fat-loss support
- Reported not to raise IGF-1 the way full growth hormone is said to
- Reported in some studies to be examined for cartilage or joint applications
Common side effects
- Injection-site redness or irritation reported
- Headache reported by some users
- Fatigue or low energy reported
- Mild nausea reported
Rare / serious side effects
- Allergic or hypersensitivity reactions reported
- Unverified effects from contaminated grey-market product
- Unknown long-term metabolic or endocrine effects
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of AOD-9604. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported use of unverified grey-market product with no approved human indication
- Reported stacking with growth-hormone secretagogues or actual GH for amplified fat loss without oversight
- Reported dosing well above amounts used in past trials in pursuit of faster results
- Reported reliance on it as a sole weight-loss method in place of medical care
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Any reported fat-loss effects are described as gradual, emerging over weeks to months rather than quickly.
First effects
Subtle appetite or energy shifts reported within the first week or two
Noticeable change
Reported gradual fat-loss support alongside diet and exercise
Clear results
Reported body-composition changes over months
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take AOD-9604. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Reported as roughly 300 mcg per day |
| Frequency | Reported as once daily, often dosed in the morning before food |
| Cycle length | Reported in multi-week blocks alongside diet and exercise; no standardised cycle exists |
Reported reconstitution (mg → units)
A 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 300 mcg (0.3 mg) dose is about 0.12 mL = 12 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorCommonly reported as daily subcutaneous use over multi-week blocks alongside diet and exercise; reported patterns vary widely and are not standardised. This is reported information, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported combined with GH secretagogues to support fat-loss goals
Reported paired for GH-axis support alongside fat metabolism
Reported discussed together as related GH-fragment fat-loss compounds
Safety notes
AOD-9604 is not an approved medicine in Australia and its long-term safety in humans is not established. Reported effects come from limited research. Anyone considering weight-related treatment should consult a qualified healthcare professional rather than relying on unapproved compounds.